Molecular Analysis for Therapy Choice (NCI-MATCH)
Molecularly targeted therapy benefits patients with defined molecular features:

within individual tumor types:
- imatinib in CML (bcr-abl)
- imatinib in GIST (CKIT & PDGFRα)
- erlotinib in NSCLC (EGFR)
- crizotinib in NSCLC (EML4-ALK)

and, across tumor types:
- trastuzumab in breast & gastric (Her-2)
- vemurafenib in melanoma, thyroid & NSCLC, but not colon cancer (BRAF)
NCI MATCH

- Identify mutations/amplifications/translocations in patient tumor sample - eligibility determination
- Assign patient to relevant agent/regimen
- Need to sequence large numbers of tumors and need to have large numbers of targeted treatments
- Tumor biopsies & sequencing at progression to illuminate resistance mechanisms
  - De-identified samples submitted to central labs
  - Whole-exome sequencing (research purposes) to detect nonambiguous germline variants
NCI-MATCH SCHEMA

1. **Genetic sequencing**
   - Actionable mutation detected
     - Study agent
       - Stable Disease, Complete or partial response (CR+PR)
       - Progressive disease (PD)
     - Check for additional actionable mutations
       - Yes
         - Continue on study agent until progression
       - No
         - No additional actionable mutations, or withdraw consent
       - Off study

1. CR, PR, SD, and PD as defined by RECIST
2. Stable disease is assessed relative to tumor status at re-initiation of study agent
3. Rebiopsy; if additional mutations, offer new targeted therapy
NCI-MATCH

- Umbrella protocol for multiple, single-arm phase II trials
  - Each molecular subgroup matched to a targeted agent
- CTEP-IND for protocol template
  - Arms could be added or deleted without affecting other arms
  - Device discussions with CDRH
- Initially focused on single-agents (commercial or experimental)
  - Combinations will be considered for targets that have validated combination targeted therapy
  - Need minimum dose/safety established in phase 1 trials
- Study will be reviewed by the CIRB
Eligibility

- Solid tumors and Lymphomas that **have progressed** following at least one line of standard therapy
  - Exclude histologies from a given arm if already FDA approved for that indication or lack of efficacy documented
- Tumor accessible for biopsy and patient willing to undergo biopsy
- At least 18 years of age
- Performance status ECOG 0-2
- Adequate organ function
Patient population considerations

- Target: at least 25% of total enrollment to be patients who have “rare” tumors

- “Common” defined as breast, NSCLC, colon, prostate

- Terminate enrollment to an arm if accrual on pace to require > 5 years to accrue
Statistical Design

(within each mutation-drug match)

- Dual Primary Endpoints: ORR 5% vs. 25% or PFS 6 months 15% vs 35%
- Simon 2-stage design 30 patients total

\[
\text{ORR} = \text{proportion of patients with objective response (PR+CR) on initial course of study agent}
\]
\[
\text{PFS6} = \text{proportion of patients alive and progression free at 6 months from initiation of study agent}
\]
Study Participation

- ECOG-ACRIN to lead with full cooperation of NCTN
  - individual PIs for each arm to rotate leadership positions
- National access through CTSU
- CCOPs
Levels of Evidence: Drugs

- **Level 1**: FDA approved; evidence of target inhibition, or proof of mechanism; demonstration that patient selection with CDx are more likely to respond
- **Level 2**: Agent met a clinical endpoint (objective response, PFS, or OS); with evidence of target inhibition; plausible evidence of a predictive or selection assay/analyte
- **Level 3**: Agent demonstrated evidence of clinical activity with evidence of target inhibition; some evidence of a predictive or selection assay/analyte
- **Level 4**: Preclinical evidence of anti-tumor activity and evidence of target inhibition; hypothesis for a predictive or selective assay/analyte
Levels of Evidence: genes

- Credentialed for selection of an approved treatment target in a particular malignancy (e.g., ERBB2 amplification and trastuzumab; BRAFV6003 and vemurafenib)
- Credentialed for selection of an approved treatment target in any malignancy but robust clinical data are lacking re: efficacy in other cancer subtypes harboring that variant.
- Gene/variant is an eligibility criteria for an ongoing clinical trial
- N of 1: response (e.g. TSC1, everolimus)
- Preclinical data
  - a. Response in at least 2 xenografts with the mutation AND no response in 2 xenografts without the mutation OR
  - b. Response in several cell lines with the mutation AND no response in cell lines without the mutation
Team Approach

- **Agent & Gene Selection Committee** vetting actionable genetic alterations and most robust agents
  - May need to recruit additional agents
  - Essential targets/pathways include: RTK, MAPK & PI3K
- **Genetic platform** developed and validated at NCI-Frederick & responses to RFA being review for extramural diagnostic centers
Over 40 drugs pledged

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Abbvie</td>
<td>• Genentech</td>
</tr>
<tr>
<td>• Amgen</td>
<td>• JNJ</td>
</tr>
<tr>
<td>• Ariad</td>
<td>• Millenium</td>
</tr>
<tr>
<td>• Biomarin</td>
<td>• Pfizer</td>
</tr>
<tr>
<td>• BMS</td>
<td>• Sanofi</td>
</tr>
<tr>
<td>• Boehringer Ingelheim</td>
<td>• Tesaro</td>
</tr>
<tr>
<td>• Clovis</td>
<td>• Tracon</td>
</tr>
<tr>
<td></td>
<td>• Verastem</td>
</tr>
</tbody>
</table>
In progress

- Currently 20 “arms”
- EGFR, HER2, MET, BRAF, NF1, GNAQ, GNA11, TSC1/2, PTEN, Patch, NF2, ALK, ROS, FGFR
Eligibility Assays

• NGS: Ion Torrent PGM with custom Ampliseq panel of 200-300 actionable genes
  – Single nucleotide variants
  – Amplifications
  – Selected translocations

• Validation in network of CLIA certified labs: RFP thru Leidos

• IHC, FISH as needed

• Rule driven treatment assignment
NGS Assay Details

- Central pre-analytic pathology laboratory
  - Biopsy receiving, specimen processing, H&E assessment, enrichment (if needed) & extraction of nucleic acids
  - Shipment to MATCH Clinical Laboratory Network for NGS assay
- Standardized SOPs for targeted Ion Torrent AmpliSeq NGS Assay
- Standard Assay report (CLIA)
Workflow and Turnover Time of the Assay System

Tissue Fixation
Path Review

Nucleic Acid Extraction

Library/Template Prep

Sequencing

Data Analysis

aMOI Report Review

Final Report

Tumor content >50%

DNA yield > 20 ng

Library yield > 10 pM

Test fragments: A/D > 80% AQ17, Read Length > 90 bp
Reads per sample: >350,000
Read Length: 140-160 bp
Coverage: >80% of amplicons coverage >450X
Positive: detect all true positive variants
Negative: detect no false positive aMOI
NTC: total reads < 2% of lowest sample library read

aMOI = actionable mutation of interest
In progress

• Nomination of investigators to guide optimal target/agent selection
  – Will become authors and PIs of study arm

• Continued engagement with patient advocates to ensure that design is responsive to patients’ needs/concerns

• Develop master protocol including elements that pertain to all arms
  – Tissue submission, result reporting, response criteria, QOL